Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 36Neoplasms 32Prostatic Neoplasms 26Colorectal Neoplasms 25Lung Neoplasms 21Carcinoma, Non-Small-Cell Lung 16Hematologic Neoplasms 13Neoplasm Metastasis 10Pancreatic Neoplasms 9Ovarian Neoplasms 8Multiple Myeloma 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Hematopoietic and Lymphatic System Neoplasm 7Stomach Neoplasms 6Carcinoma, Renal Cell 6Anatomic Stage I Breast Cancer AJCC v8 6Uterine Cervical Neoplasms 5Sarcoma 5Glioma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Mouth Neoplasms 4Motor Activity 4Melanoma 4Leukemia, Myeloid, Acute 4Hematopoietic and Lymphoid System Neoplasm 4Head and Neck Carcinoma 4Gastrointestinal Neoplasms 4

Interventions

olaparib 4Pluvicto 4Abiraterone Acetate 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1cabozantinib 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Standard of Care × 1 year × Clear all
NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡